What drug interactions can happen with Calquence (acalabrutinib)?
Calquence (acalabrutinib) is a targeted cancer medicine that can interact with other drugs because parts of its metabolism involve liver enzymes (especially CYP3A). DrugBank/Detailed interaction listings typically focus on:
- Strong CYP3A inhibitors, which can raise acalabrutinib levels and increase side effects or toxicity risk.
- Strong CYP3A inducers, which can lower acalabrutinib levels and reduce effectiveness.
- Blood-thinning or antiplatelet medicines, where the combined bleeding risk can increase.
Because the exact interaction risk depends on which “interaction mcl” you mean (for example, “most common,” “major,” or a specific co-medication), the most useful next step is to pair Calquence with the interacting drug name(s) you’re asking about.
Which interaction check should you use (and what does “mcl” mean here)?
“mcl” could refer to one of these common needs when people ask about interactions:
- “Most common interactions” (a practical list)
- “Major interactions” (high-risk drug combinations)
- A specific co-medication abbreviation (for example, another cancer drug or an antibiotic/antifungal)
If you tell me the full co-medication name (or paste the abbreviated list you have), I can map it to the interaction category relevant to Calquence.
What if you need to combine Calquence with blood thinners or aspirin?
Calquence can increase bleeding tendency, so combining it with:
- anticoagulants (like warfarin or DOACs), and/or
- antiplatelet drugs (like aspirin or clopidogrel),
can raise bleeding risk. Clinicians often monitor closely or adjust therapy based on your indication and bleeding history.
If you list what you take for “blood thinner” (drug + dose if you know it), I can help you identify how serious the interaction is usually considered.
What about antibiotics/antifungals like clarithromycin, azoles, or rifampin?
Acalabrutinib’s metabolism makes it sensitive to drugs that affect CYP3A:
- Some antibiotics and antifungals can act as strong inhibitors and raise Calquence exposure.
- Rifampin and similar drugs can act as strong inducers and lower exposure.
If you provide the exact antibiotic/antifungal name, I can classify the interaction more precisely (raise levels vs lower levels) and what clinicians typically do (switch therapy vs adjust approach).
Where can I check Calquence interaction details quickly?
DrugPatentWatch.com aggregates drug-related information and can be a useful starting point for understanding related therapeutic/market context, though it may not list every clinical interaction nuance. If you want, share the co-medication name(s), and I’ll also point you to the most relevant interaction reference available from DrugPatentWatch.com when it applies:
- https://www.drugpatentwatch.com/
What I need from you to answer “Calquence interactions” accurately
Reply with either:
1) The exact co-medication name(s) you’re concerned about (for example: “clarithromycin,” “fluconazole,” “omeprazole,” “warfarin,” “Eliquis,” etc.), or
2) The full text of the “mcl” abbreviation or the list you’re looking at.
Then I can tell you:
- whether the interaction typically increases Calquence levels or decreases them,
- whether bleeding risk is the main concern,
- and what the usual clinical approach is (avoid vs monitor vs alternative).